Search results
Results From The WOW.Com Content Network
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
2019 31 December 2019 RMB 255.63 [29] $46.36 49 Microsoft Information technology United States: 2019 30 June 2019 $39.24 [30] $46.76 50 China Construction Bank Banking China: 2017 31 December 2017 RMB 243.615 [34] $46.5 51: Royal Dutch Shell: Oil and gas Netherlands UK: 2007: 31 December 2007: $31.33 [35] $46.04 52: China Construction Bank ...
Pfizer raised its annual profit forecast on Tuesday, helped by cancer treatments acquired through a $43 billion deal for Seagen and strong sales of its heart disease drug as the company deals with ...
Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. Its forecast for 2019 falls short of expectations. Stock dips 2% in pre-market trading.
Margins matter. The more Pfizer (NYS: PFE) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders.
The drugs are expected to bring in more than $4 billion this year. Pfizer said it still expects $8 billion in combined sales of its COVID-19 products, the vaccine Comirnaty it shares with BionTech ...
Investors fled Pfizer last year as pandemic worries declined and billions of dollars in COVID-19 vaccine and treatment sales disappeared. Pfizer posts surprise 4th quarter profit, but key products ...
Elise Amendola/AP Pfizer reported lower-than-expected quarterly earnings and revenue, and the largest U.S. drugmaker trimmed its full-year profit outlook, sending its shares down 3 percent. The ...